Thomas Eigentler

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

Medicine, Clinical Sciences, Oncology +15

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2020 · 650 citations

Pharmacy, Oncology, Pharmacotherapy +15

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Lars Hofmann, Andrea Forschner, Carmen Loquai et al. · European Journal of Cancer · 2016 · 647 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Lisa Zimmer, Simone M. Goldinger, Lars Hofmann et al. · European Journal of Cancer · 2016 · 560 citations

Medicine, Pharmacology, Pharmacotherapy +11

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba‐Hamprecht, Marnix Geukes Foppen et al. · Clinical Cancer Research · 2016 · 542 citations · Full text

Medicine, Immunology, Oncology +17